1
|
Hurtado-Genovés G, Herrero-Cervera A, Vinué Á, Martín-Vañó S, Aguilar-Ballester M, Taberner-Cortés A, Jiménez-Martí E, Martínez-Hervás S, González-Navarro H. Light deficiency in Apoe-/-mice increases atheroma plaque size and vulnerability by modulating local immunity. Biochim Biophys Acta Mol Basis Dis 2024; 1870:167052. [PMID: 38336102 DOI: 10.1016/j.bbadis.2024.167052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 01/29/2024] [Accepted: 02/01/2024] [Indexed: 02/12/2024]
Abstract
Previous research suggests a potential involvement of the cytokine LIGHT (TNFSF14) in atherosclerosis. In this study, the genetic inactivation of Light in Apolipoprotein E deficient mice (male and female C57BL) augmented plaque size and vulnerability while decreasing Treg cells. Human and mouse transcriptomic results demonstrated deranged immune pathways in human atheromas with low LIGHT expression levels and in Light-deficient murine atheromas. In agreement with this, in vitro LIGHT-treatment of human lymphocytes, induced an elevation of Treg cell prevalence while proteomic analysis showed a downregulation of apoptotic and leukocyte cytotoxic pathways. Consistently, Light-deficient mouse lesions displayed increased plaque apoptosis and detrimental adventitial T-lymphocyte aggregates. Altogether suggested that LIGHT could promote a Treg prevalence in the local immunity to prevent the generation of vulnerable plaques via decreased cytotoxic microenvironment and apoptosis. Light gene delivery in Apoe-/-Light-/- mice, through bone marrow transplantation approaches, consistently diminished lesion size and restored local plaque immunity. Altogether demonstrate that Light-deficiency promotes atheroma plaque progression, at least in part through local loss of immune homeostasis and increased apoptosis. This study suggest that therapies based on the local delivery of LIGHT within plaques might therefore prevent immune cell derangement and advanced atherosclerosis.
Collapse
Affiliation(s)
| | | | - Ángela Vinué
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain
| | | | | | | | - Elena Jiménez-Martí
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain; Biochemistry and Molecular Biology Department, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain
| | - Sergio Martínez-Hervás
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain; Endocrinology and Nutrition Department, Clinic Hospital and Department of Medicine, University of Valencia, 46010 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Herminia González-Navarro
- INCLIVA Biomedical Research Institute, 46010 Valencia, Spain; Biochemistry and Molecular Biology Department, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.
| |
Collapse
|
2
|
Maier-Begandt D, Alonso-Gonzalez N, Klotz L, Erpenbeck L, Jablonska J, Immler R, Hasenberg A, Mueller TT, Herrero-Cervera A, Aranda-Pardos I, Flora K, Zarbock A, Brandau S, Schulz C, Soehnlein O, Steiger S. Neutrophils - Biology and Diversity. Nephrol Dial Transplant 2023:gfad266. [PMID: 38115607 DOI: 10.1093/ndt/gfad266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2023] Open
Abstract
Neutrophils, the most abundant white blood cells in the human circulation, play crucial roles in various diseases, including kidney disease. Traditionally viewed as short-lived pro-inflammatory phagocytes that release reactive oxygen species, cytokines and neutrophil extracellular traps, recent studies have revealed their complexity and heterogeneity, thereby challenging this perception. Neutrophils are now recognized as transcriptionally active cells capable of proliferation and reverse migration, displaying phenotypic and functional heterogeneity. They respond to a wide range of signals and deploy various cargo to influence the activity of other cells in the circulation and in tissues. They can regulate the behavior of multiple immune cell types, exhibit innate immune memory, and contribute to both acute and chronic inflammatory responses while also promoting inflammation resolution in a context-dependent manner. Here, we explore the origin and heterogeneity of neutrophils, their functional diversity, and the cues that regulate their effector functions. We also examine their emerging role in infectious and non-infectious diseases with a particular emphasis on kidney disease. Understanding the complex behavior of neutrophils during tissue injury and inflammation may provide novel insights, thereby paving the way for potential therapeutic strategies to manage acute and chronic conditions. By deciphering their multifaceted role, targeted interventions can be developed to address the intricacies of neutrophil-mediated immune responses and improve disease outcomes.
Collapse
Affiliation(s)
- Daniela Maier-Begandt
- Institute of Cardiovascular Physiology and Pathophysiology, Walter Brendel Center for Experimental Medicine Biomedical Center (BMC), Ludwig-Maximilians-Universität München, Munich, Germany
| | | | - Luisa Klotz
- Department of Neurology with Institute for Translational Neurology, University Hospital Münster, Münster, Germany
| | - Luise Erpenbeck
- Department of Dermatology, University Hospital Münster, Münster, Germany
| | - Jadwiga Jablonska
- Department of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- German Cancer Consortium (DKTK) partner site Düsseldorf/Essen, Essen, Germany
| | - Roland Immler
- Institute of Cardiovascular Physiology and Pathophysiology, Walter Brendel Center for Experimental Medicine Biomedical Center (BMC), Ludwig-Maximilians-Universität München, Munich, Germany
| | - Anja Hasenberg
- Institute of Experimental Immunology and Imaging, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Tonina T Mueller
- Department of Medicine I, Ludwig-Maximilians-University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Andrea Herrero-Cervera
- Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Universität of Münster, Münster, Germany
| | | | - Kailey Flora
- Renal Division, Department of Medicine IV, Ludwig-Maximilians-University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Alexander Zarbock
- Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
| | - Sven Brandau
- Department of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Christian Schulz
- Department of Medicine I, Ludwig-Maximilians-University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Oliver Soehnlein
- Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Universität of Münster, Münster, Germany
| | - Stefanie Steiger
- Renal Division, Department of Medicine IV, Ludwig-Maximilians-University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| |
Collapse
|
3
|
Pan C, Herrero-Fernandez B, Borja Almarcha C, Gomez Bris R, Zorita V, Sáez A, Maas SL, Pérez-Olivares L, Herrero-Cervera A, Lemnitzer P, van Avondt K, Silvestre-Roig C, Gonzalez-Granado JM, Chevre R, Soehnlein O. Time-Restricted Feeding Enhances Early Atherosclerosis in Hypercholesterolemic Mice. Circulation 2023; 147:774-777. [PMID: 36848415 DOI: 10.1161/circulationaha.122.063184] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Affiliation(s)
- Chang Pan
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Beatriz Herrero-Fernandez
- LamImSys Lab, Instituto de Investigación Sanitaria Hospital), Madrid, Spain (B.H.-F., R.G.B., A.S., J.M.G.-G.).,Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Spain (B.H.-F., R.G.B.)
| | - Celia Borja Almarcha
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Raquel Gomez Bris
- LamImSys Lab, Instituto de Investigación Sanitaria Hospital), Madrid, Spain (B.H.-F., R.G.B., A.S., J.M.G.-G.).,Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Spain (B.H.-F., R.G.B.)
| | - Virginia Zorita
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (V.Z., J.M.G.-G.)
| | - Angela Sáez
- LamImSys Lab, Instituto de Investigación Sanitaria Hospital), Madrid, Spain (B.H.-F., R.G.B., A.S., J.M.G.-G.).,Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain (A.S.)
| | - Sanne Lidewij Maas
- Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Laura Pérez-Olivares
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Andrea Herrero-Cervera
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.)
| | - Patricia Lemnitzer
- Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Kristof van Avondt
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Carlos Silvestre-Roig
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Jose Maria Gonzalez-Granado
- LamImSys Lab, Instituto de Investigación Sanitaria Hospital), Madrid, Spain (B.H.-F., R.G.B., A.S., J.M.G.-G.).,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (V.Z., J.M.G.-G.).,Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense de Madrid, Spain (J.M.G.-G.).,CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (J.M.G.-G.)
| | - Raphael Chevre
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.)
| | - Oliver Soehnlein
- Institute of Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), Münster, Germany (C.P., C.B.A., L.P.-O. A.H.-C., K.v.A., C.S.-R., R.C., O.S.).,Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany (C.P., C.B.A., S.L.M., L.P.-O., P.L., K.v.A., C.S.-R., R.C., O.S.).,Department of Physiology and Pharmacology (FyFa), Karolinska Institute, Stockholm, Sweden (O.S.)
| |
Collapse
|
4
|
Martín-Vañó S, Miralles-Abella A, Castaño P, Hurtado-Genovés G, Aguilar-Ballester M, Herrero-Cervera A, Vinué A, Martínez-Hervás S, González-Navarro H. Vascular smooth muscle cell phenotype is modulated by ligands of the lymphotoxin β receptor and the tumor necrosis factor receptor. Clin Investig Arterioscler 2023; 35:1-11. [PMID: 35738949 DOI: 10.1016/j.arteri.2022.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/18/2022] [Accepted: 05/22/2022] [Indexed: 02/08/2023]
Abstract
OBJECTIVE Vascular smooth muscle cells (VSMCs) undergo a phenotypic-switching process during the generation of unstable atheroma plaques. In this investigation, the potential implication of the tumor necrosis factor superfamily (TNFSF) ligands, in the gene expression signature associated with VSMC plasticity was studied. MATERIAL AND METHODS Human aortic (ha)VSMCs were obtained commercially and treated with the cytokine TNFSF14, also called LIGHT, the lymphotoxin alpha (LTα), the heterotrimer LTα1β2 or with vehicle for 72h. The effect of the different treatments on gene expression was analyzed by quantitative PCR and included the study of genes associated with myofibroblast-like cell function, osteochondrogenesis, pluripotency, lymphorganogenesis and macrophage-like cell function. RESULTS HaVSMCs displayed a change in myofibroblast-like cell genes which consisted in reduced COL1A1 and TGFB1 mRNA levels when treated with LTα or LIGHT and with augmented MMP9 expression levels when treated with LTα. LTα and LIGHT treatments also diminished the expression of genes associated with osteochondrogenesis and pluripotency SOX9, CKIT, and KLF4. By contrary, all the above genes were no affected by the treatment with the trimer LTα1β2. In addition, haVSMC treatment with LTα, LTα1β2 and LIGHT altered lymphorganogenic cytokine gene expression which consisted of augmented CCL20 and CCL21 mRNA levels by LTα and a reduction in the gene expression of CCL21 and CXCL13 by LIGHT and LTα1β2 respectively. Neither, LTα or LIGHT or LTα1β2 treatments affected the expression of macrophage-like cell markers in haVSMC. CONCLUSIONS Altogether, indicates that the TNFSF ligands through their interconnected network of signaling, are important in the preservation of VSMC identity against the acquisition of a genetic expression signature compatible with functional cellular plasticity.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Angela Vinué
- Institute of Health Research-INCLIVA, Valencia, Spain
| | - Sergio Martínez-Hervás
- Institute of Health Research-INCLIVA, Valencia, Spain; Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVA, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Biochemistry and Molecular Biology Department, Faculty of Medicine, University of Valencia, Valencia, Spain.
| |
Collapse
|
5
|
Hurtado Genovés G, Martín-Vañó S, Herrero-Cervera A, Aguilar-Ballester M, Vinué Á, Taberner Cortés A, Martínez-Hervás S, González-Navarro H. Light deficiency in Apoe-/- mice increases atheroma plaque vulnerability by modulating artery tertiary lymphoid organs. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Ballester MA, Martín-Vañó S, Miralles AA, Genovés GH, Herrero-Cervera A, Cortés AT, Vinué Á, Martínez-Hervás S, González-Navarro H. Role of LTΑ/TNFR and LTΑ1Β2/LTΒR axis in vascular smooth muscle cells in the context of atherosclerosis. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
7
|
Abstract
Chronic inflammation is a component of many disease conditions that affect a large group of individuals worldwide. Chronic inflammation is characterized by persistent, low-grade inflammation and is increased in the aging population. Neutrophils are normally the first responders to acute inflammation and contribute to the resolution of inflammation. However, in chronic inflammation, the role of neutrophils is less well understood and has been described as either beneficial or detrimental, causing tissue damage and enhancing the immune response. Emerging evidence suggests that neutrophils are important players in several chronic diseases, such as atherosclerosis, diabetes mellitus, nonalcoholic fatty liver disease and autoimmune disorders. This review will highlight the interaction of neutrophils with other cells in the context of chronic inflammation, the contribution of neutrophils to selected chronic inflammatory diseases, and possible future therapeutic strategies.
Collapse
Affiliation(s)
- Andrea Herrero-Cervera
- Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität Münster, Münster, Germany.
| | - Oliver Soehnlein
- Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität Münster, Münster, Germany
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Ellinor Kenne
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
8
|
Herrero-Cervera A, Espinós-Estévez C, Martín-Vañó S, Taberner-Cortés A, Aguilar-Ballester M, Vinué Á, Piqueras L, Martínez-Hervás S, González-Navarro H. Dissecting Abdominal Aortic Aneurysm Is Aggravated by Genetic Inactivation of LIGHT (TNFSF14). Biomedicines 2021; 9:biomedicines9111518. [PMID: 34829747 PMCID: PMC8615201 DOI: 10.3390/biomedicines9111518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 10/18/2021] [Accepted: 10/19/2021] [Indexed: 11/16/2022] Open
Abstract
Abdominal aortic aneurysm (AAA), is a complex disorder characterized by vascular vessel wall remodeling. LIGHT (TNFSF14) is a proinflammatory cytokine associated with vascular disease. In the present study, the impact of genetic inactivation of Light was investigated in dissecting AAA induced by angiotensin II (AngII) in the Apolipoprotein E-deficient (Apoe−/−) mice. Studies in aortic human (ah) vascular smooth muscle cells (VSMC) to study potential translation to human pathology were also performed. AngII-treated Apoe−/−Light−/− mice displayed increased abdominal aorta maximum diameter and AAA severity compared with Apoe−/− mice. Notably, reduced smooth muscle α-actin+ area and Acta2 and Col1a1 gene expression were observed in AAA from Apoe−/−Light−/− mice, suggesting a loss of VSMC contractile phenotype compared with controls. Decreased Opn and augmented Sox9 expression, which are associated with detrimental and non-contractile osteochondrogenic VSMC phenotypes, were also seen in AngII-treated Apoe−/−Light−/− mouse AAA. Consistent with a role of LIGHT preserving VSMC contractile characteristics, LIGHT-treatment of ahVSMCs diminished the expression of SOX9 and of the pluripotency marker CKIT. These effects were partly mediated through lymphotoxin β receptor (LTβR) as the silencing of its gene ablated LIGHT effects on ahVSMCs. These studies suggest a protective role of LIGHT through mechanisms that prevent VSMC trans-differentiation in an LTβR-dependent manner.
Collapse
Affiliation(s)
- Andrea Herrero-Cervera
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
| | | | - Susana Martín-Vañó
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
| | - Alida Taberner-Cortés
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
| | - María Aguilar-Ballester
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
| | - Ángela Vinué
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
| | - Laura Piqueras
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
- Department of Pharmacology, University of Valencia, 46010 Valencia, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
| | - Sergio Martínez-Hervás
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
- Endocrinology and Nutrition Service, Clinic Hospital of Valencia, 46010 Valencia, Spain
- Department of Medicine, University of Valencia, 46010 Valencia, Spain
| | - Herminia González-Navarro
- INCLIVA, Institute of Health Research, 46010 Valencia, Spain; (A.H.-C.); (S.M.-V.); (A.T.-C.); (M.A.-B.); (Á.V.); (L.P.); (S.M.-H.)
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
- Biochemistry and Molecular Biology Department, University of Valencia, 46010 Valencia, Spain
- Correspondence: ; Tel.: +34-96-386-44-03; Fax: +34-96-398-78-60
| |
Collapse
|
9
|
Taberner-Cortés A, Vinué Á, Herrero-Cervera A, Aguilar-Ballester M, Real JT, Burks DJ, Martínez-Hervás S, González-Navarro H. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance. Int J Mol Sci 2020; 21:ijms21239216. [PMID: 33287201 PMCID: PMC7730942 DOI: 10.3390/ijms21239216] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/27/2020] [Accepted: 12/01/2020] [Indexed: 12/16/2022] Open
Abstract
Type 2 diabetes mellitus (T2DM) increases morbimortality in humans via enhanced susceptibility to cardiovascular disease (CVD). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are drugs designed for T2DM treatment to diminish hyperglycaemia by reducing up to 90% of renal tube glucose reabsorption. Clinical studies also suggest a beneficial action of SGLT2i in heart failure and CVD independent of its hypoglycaemiant effect. In the present study, we explored the effect of SGLT2i dapagliflozin (DAPA) in the metabolism and atherosclerosis in Apoe−/−Irs2+/− mice, which display accelerated atherosclerosis induced by insulin resistance. DAPA treatment of Apoe−/−Irs2+/− mice, which were fed a high-fat, high-cholesterol diet, failed to modify body weight, plasma glucose or lipid. Carbohydrate metabolism characterisation showed no effect of DAPA in the glucose tolerance test (GTT) despite augmented insulin levels during the test. In fact, decreased C-peptide levels in DAPA-treated mice during the GTT suggested impaired insulin release. Consistent with this, DAPA treatment of Apoe−/−Irs2+/− isolated islets displayed lower glucose-stimulated insulin secretion compared with vehicle-treated islets. Moreover, insulin-signalling experiments showed decreased pAKT activation in DAPA-treated adipose tissue indicating impaired insulin signalling in this tissue. No changes were seen in lesion size, vulnerability or content of macrophages, vascular smooth muscle cells, T cells or collagen. DAPA did not affect circulating inflammatory cells or cytokine levels. Hence, this study indicates that DAPA does not protect against atherosclerosis in insulin-resistant mice in hypercholesterolemic conditions.
Collapse
Affiliation(s)
- Alida Taberner-Cortés
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
| | - Ángela Vinué
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
| | - Andrea Herrero-Cervera
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
| | - María Aguilar-Ballester
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
| | - José Tomás Real
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
- Endocrinology and Nutrition Service, Clinic Hospital of Valencia, 46010 Valencia, Spain
- Department of Medicine, University of Valencia, 46010 Valencia, Spain
- CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain;
| | - Deborah Jane Burks
- CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain;
- CIPF Principe Felipe Research Center, 46012 Valencia, Spain
| | - Sergio Martínez-Hervás
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
- Endocrinology and Nutrition Service, Clinic Hospital of Valencia, 46010 Valencia, Spain
- Department of Medicine, University of Valencia, 46010 Valencia, Spain
- CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain;
| | - Herminia González-Navarro
- Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain; (A.T.-C.); (Á.V.); (A.H.-C.); (M.A.-B.); (J.T.R.); (S.M.-H.)
- CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain;
- Correspondence: ; Tel.: +34-96-386-4403
| |
Collapse
|
10
|
Fuster JJ, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, Ferrer-Pérez A, Matesanz N, Herrero-Cervera A, Sano S, Cooper MA, González-Navarro H, Walsh K. TET2-Loss-of-Function-Driven Clonal Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity. Cell Rep 2020; 33:108326. [PMID: 33113366 PMCID: PMC7856871 DOI: 10.1016/j.celrep.2020.108326] [Citation(s) in RCA: 98] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 09/18/2020] [Accepted: 10/07/2020] [Indexed: 01/10/2023] Open
Abstract
Human aging is frequently accompanied by the acquisition of somatic mutations in the hematopoietic system that induce clonal hematopoiesis, leading to the development of a mutant clone of hematopoietic progenitors and leukocytes. This somatic-mutation-driven clonal hematopoiesis has been associated with an increased incidence of cardiovascular disease and type 2 diabetes, but whether this epidemiological association reflects a direct, causal contribution of mutant hematopoietic and immune cells to age-related metabolic abnormalities remains unexplored. Here, we show that inactivating mutations in the epigenetic regulator TET2, which lead to clonal hematopoiesis, aggravate age- and obesity-related insulin resistance in mice. This metabolic dysfunction is paralleled by increased expression of the pro-inflammatory cytokine IL-1β in white adipose tissue, and it is suppressed by pharmacological inhibition of NLRP3 inflammasome-mediated IL-1β production. These findings support a causal contribution of somatic TET2 mutations to insulin resistance and type 2 diabetes.
Collapse
Affiliation(s)
- José J Fuster
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Boston University School of Medicine, Boston, MA, USA.
| | - María A Zuriaga
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Boston University School of Medicine, Boston, MA, USA
| | - Virginia Zorita
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | | | | | - Vanesa Viana-Huete
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
| | - Alba Ferrer-Pérez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Nuria Matesanz
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Andrea Herrero-Cervera
- Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA; Institute of Health Research-INCLIVA, Valencia, Spain
| | - Soichi Sano
- Boston University School of Medicine, Boston, MA, USA; Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
| | - Matthew A Cooper
- Institute for Molecular Bioscience, University of Queensland, QLD, Australia
| | - Herminia González-Navarro
- Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA; Institute of Health Research-INCLIVA, Valencia, Spain; Department of Didactics of Experimental and Social Sciences, University of Valencia, Valencia, Spain; CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain
| | - Kenneth Walsh
- Boston University School of Medicine, Boston, MA, USA; Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA.
| |
Collapse
|
11
|
Aguilar-Ballester M, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, González-Navarro H. Impact of Cholesterol Metabolism in Immune Cell Function and Atherosclerosis. Nutrients 2020; 12:nu12072021. [PMID: 32645995 PMCID: PMC7400846 DOI: 10.3390/nu12072021] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 06/29/2020] [Accepted: 07/02/2020] [Indexed: 12/24/2022] Open
Abstract
Cholesterol, the most important sterol in mammals, helps maintain plasma membrane fluidity and is a precursor of bile acids, oxysterols, and steroid hormones. Cholesterol in the body is obtained from the diet or can be de novo synthetized. Cholesterol homeostasis is mainly regulated by the liver, where cholesterol is packed in lipoproteins for transport through a tightly regulated process. Changes in circulating lipoprotein cholesterol levels lead to atherosclerosis development, which is initiated by an accumulation of modified lipoproteins in the subendothelial space; this induces significant changes in immune cell differentiation and function. Beyond lesions, cholesterol levels also play important roles in immune cells such as monocyte priming, neutrophil activation, hematopoietic stem cell mobilization, and enhanced T cell production. In addition, changes in cholesterol intracellular metabolic enzymes or transporters in immune cells affect their signaling and phenotype differentiation, which can impact on atherosclerosis development. In this review, we describe the main regulatory pathways and mechanisms of cholesterol metabolism and how these affect immune cell generation, proliferation, activation, and signaling in the context of atherosclerosis.
Collapse
Affiliation(s)
- María Aguilar-Ballester
- INCLIVA Institute of Health Research, 46010 Valencia, Spain; (M.A.-B.); (A.H.-C.); (Á.V.); (S.M.-H.)
| | - Andrea Herrero-Cervera
- INCLIVA Institute of Health Research, 46010 Valencia, Spain; (M.A.-B.); (A.H.-C.); (Á.V.); (S.M.-H.)
| | - Ángela Vinué
- INCLIVA Institute of Health Research, 46010 Valencia, Spain; (M.A.-B.); (A.H.-C.); (Á.V.); (S.M.-H.)
| | - Sergio Martínez-Hervás
- INCLIVA Institute of Health Research, 46010 Valencia, Spain; (M.A.-B.); (A.H.-C.); (Á.V.); (S.M.-H.)
- Endocrinology and Nutrition Department Clinic Hospital and Department of Medicine, University of Valencia, 46010 Valencia, Spain
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
| | - Herminia González-Navarro
- INCLIVA Institute of Health Research, 46010 Valencia, Spain; (M.A.-B.); (A.H.-C.); (Á.V.); (S.M.-H.)
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
- Department of Didactics of Experimental and Social Sciences, University of Valencia, 46010 Valencia, Spain
- Correspondence: ; Tel.: +34-963864403; Fax: +34-963987860
| |
Collapse
|
12
|
Herrero-Cervera A, Vinué Á, Burks DJ, González-Navarro H. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis. Diabetologia 2019; 62:2143-2157. [PMID: 31388695 DOI: 10.1007/s00125-019-4962-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 06/10/2019] [Indexed: 12/27/2022]
Abstract
AIMS/HYPOTHESIS Non-alcoholic fatty liver disease (NAFLD) is frequently associated with type 2 diabetes mellitus. Progression of NAFLD is mediated, among other things, by activation of inflammatory pathways. In the present study, the role of the proinflammatory cytokine LIGHT (TNFSF14) was explored in NAFLD and type 2 diabetes mellitus in mice deficient for the cytokine. METHODS Light-deficient (Light-/-) mice and WT controls were fed a regular chow diet (RCD) or a high-fat high-cholesterol diet (HFHCD) for 16 weeks. The expression of LIGHT and its receptors, herpes virus entry mediator (HVEM) and lymphotoxin β receptor (LTβR), was investigated in both dietary regimens. Glucose tolerance, insulin sensitivity, non-alcoholic fatty liver (NAFL), systemic and tissue inflammation, and metabolic gene expression were explored in Light-/- and WT mice fed an RCD and an HFHCD. The effect of Light deficiency was also evaluated in hepatic tissue and in inflammation in HFHCD-fed Irs2+/- mice with impaired insulin signalling. RESULTS Light deficiency did not have an effect on metabolism, in NAFL or in tissue and systemic inflammation, in RCD-fed WT mice. HVEM and LTβR were markedly increased in livers of HFHCD-fed WT mice compared with RCD-fed WT controls. In WT mice under HFHCD, Light deficiency improved glucose tolerance and insulin sensitivity. Non-alcoholic fatty liver disease activity (NAS) score, hepatic CD3+ T lymphocytes and F4/80+ macrophages were decreased in HFHCD-fed Light-/- mice compared with HFHCD-fed WT controls. Consistent with a potential role of adipose tissue in hepatic homeostasis, Light-/- mice exhibited augmented anti-inflammatory F4/80+CD206+ adipose tissue macrophages and reduced proinflammatory F4/80+CD11c+ adipose tissue macrophages. Moreover, adipose tissue explants from Light-/- mice showed diminished secretion of monocyte chemoattractant protein 1 (MCP1), TNF-α and IL-17 cytokines. Circulating Light-/- leucocytes consistently displayed augmented levels of the patrolling Ly6Clow monocytes, decreased Th9 T cell subset and diminished plasma TNF-α and IL-6 levels. Similarly, Light deficiency in Irs2+/- mice, which display impaired insulin signalling, also reduced NAFL as well as systemic and adipose tissue inflammation. Analysis of hepatic gene expression in Light-/- mouse livers showed reduced levels of Zbtb16, the transcription factor essential for natural killer T (NKT) cell function, and two genes related to NAFLD and fibrosis, Klf6 and Tlr4. CONCLUSIONS/INTERPRETATION These results indicate that Light deficiency in HFHCD improves hepatic glucose tolerance, and reduces hepatic inflammation and NAFL. This is accompanied by decreased systemic inflammation and adipose tissue cytokine secretion and by changes in the expression of key genes such as Klf6 and Tlr4 involved in NAFLD. These results suggest that therapies to block LIGHT-dependent signalling might be useful to restore hepatic homeostasis and to restrain NAFLD.
Collapse
Affiliation(s)
| | - Ángela Vinué
- INCLIVA Health Research Institute, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain
| | - Deborah J Burks
- The Prince Felipe Research Center (CIPF), Valencia, Spain
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain
| | - Herminia González-Navarro
- INCLIVA Health Research Institute, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), Madrid, Spain.
- Department of Didactics of Experimental and Social Sciences, University of Valencia, Valencia, Spain.
| |
Collapse
|
13
|
Martínez-Hervás S, Sánchez-García V, Herrero-Cervera A, Vinué Á, Real JT, Ascaso JF, Burks DJ, González-Navarro H. Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes. J Transl Med 2019; 17:222. [PMID: 31299986 PMCID: PMC6626385 DOI: 10.1186/s12967-019-1977-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 07/08/2019] [Indexed: 12/12/2022] Open
Abstract
Background Type 1 diabetes mellitus (T1DM) patients display increased risk of cardiovascular disease (CVD) and are characterized by a diminished regulatory T (Treg) cell content or function. Previous studies have shown an association between decreased CDKN2A/2B/2BAS gene expression and enhanced CVD. In the present study the potential relationship between CDKN2A/2B/2BAS gene expression, immune cell dysfunction and increased cardiovascular risk in T1DM patients was explored. Methods A cross-sectional study was performed in 90 subjects divided into controls and T1DM patients. Circulating leukocyte subpopulations analysis by flow cytometry, expression studies on peripheral blood mononuclear cell by qPCR and western blot and correlation studies were performed in both groups of subjects. Results Analysis indicated that, consistent with the described T cell dysfunction, T1DM subjects showed decreased circulating CD4+CD25+CD127− Treg cells. In addition, T1DM subjects had lower mRNA levels of the transcription factors FOXP3 and RORC and lower levels of IL2 and IL6 which are involved in Treg and Th17 cell differentiation, respectively. T1DM patients also exhibited decreased mRNA levels of CDKN2A (variant 1 p16Ink4a), CDKN2A (p14Arf,variant 4), CDKN2B (p15Ink4b) and CDKN2BAS compared with controls. Notably, T1DM patients had augmented pro-atherogenic CD14++CD16+-monocytes, which predict cardiovascular acute events and enhanced common carotid intima-media thickness (CC-IMT). Conclusions Decreased expression of CDKN2A/2B/2BAS in leukocytes associates with increased CC-IMT atherosclerosis surrogate marker and proatherogenic CD14++CD16+ monocytes in T1DM patients. These results suggest a potential role of CDKN2A/2B/2BAS genes in CVD risk in T1DM. Electronic supplementary material The online version of this article (10.1186/s12967-019-1977-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sergio Martínez-Hervás
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | | | | | - Ángela Vinué
- INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain
| | - José Tomás Real
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | - Juan F Ascaso
- Endocrinology and Nutrition Department Hospital Clínico Universitario. Department of Medicine, University of Valencia, 46010, Valencia, Spain.,INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain.,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain
| | - Deborah Jane Burks
- CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain.,Príncipe Felipe Research Center (CIPF), 46012, Valencia, Spain
| | - Herminia González-Navarro
- INCLIVA Institute of Health Research, Avda. Menéndez Pelayo, 4, 46010, Valencia, Spain. .,CIBER Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029, Madrid, Spain. .,Department of Didactics of Experimental and Social Sciences, University of Valencia, 46010, Valencia, Spain.
| |
Collapse
|
14
|
Andrés-Blasco I, Vinué À, Herrero-Cervera A, Martínez-Hervás S, Nuñez L, Piqueras L, Ascaso JF, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase inactivation decreases atherosclerosis in insulin resistance by reducing LIGHT/Lymphotoxin β-Receptor pathway. Thromb Haemost 2018; 116:379-93. [DOI: 10.1160/th15-10-0773] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 04/24/2016] [Indexed: 01/03/2023]
Abstract
SummaryCoexistence of insulin resistance (IR) and metabolic syndrome (MetS) increases the risk of cardiovascular disease (CVD). Genetic studies in diabetes have linked Hepatic Lipase (HL) to an enhanced risk of CVD while others indicate a role of HL in inflammatory cells. Thus, we explored the role of HL on atherosclerosis and inflammation in a mouse model of MetS/IR, (apoE-/-Irs2+/- mice) and in patients with MetS and IR. HL-deficiency in apoE-/-Irs2+/- mice reduced atheroma size, plaque vulnerability, leukocyte infiltration and macrophage proliferation. Compared with apoE-/-Irs2+/-HL+/+ mice, MCP1, TNFa and IL6 plasma levels, pro-inflammatory Ly6Chi monocytes and activated(CD69+)-T lymphocytes were also decreased in apoE-/-Irs2+/-HL-/- mice. The LIGHT (Tumour necrosis factor ligand superfamily member 14, TNFSF14)/ Lymphotoxin β-Receptor(LTβ-R) pathway, which is involved in T-cell and macrophage activation, was diminished in plasma and in apoE-/-Irs2+/-HL-/- mouse atheromas. Treatment of apoE-/-Irs2+/-HL-/- mice with LIGHT increased the number of Ly6Chi-monocytes and lesion size. Acutely LIGHT-treated apoE-/- mice displayed enhanced proliferating Ly6Chi-monocytes and increased activation of the mitogen-activated protein kinase p38, suggesting that LIGHT/LTβ-R axis might promote atherogenesis by increasing proinflammatory monocytes and proliferation. Notably, MetS-IR subjects with increased atherosclerosis displayed up-regulation of the LIGHT/LTβ-R axis, enhanced inflammatory monocytes and augmented HL mRNA expression in circulating leukocytes. Thus, HL-deficiency decreases atherosclerosis in MetS/IR states by reducing inflammation and macrophage proliferation which are partly attributed to reduced LIGHT/LTβ-R pathway. These studies identify the LIGHT/LTβ-R axis as a main pathway in atherosclerosis and suggest that its inactivation might ameliorate inflammation and macrophage proliferation associated with atherosclerosis burden in MetS/IR.Supplementary Material to this article is available at www.thrombosis-online.com.
Collapse
|
15
|
Vinué Á, Navarro J, Herrero-Cervera A, García-Cubas M, Andrés-Blasco I, Martínez-Hervás S, Real JT, Ascaso JF, González-Navarro H. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 2017; 60:1801-1812. [PMID: 28608285 DOI: 10.1007/s00125-017-4330-3] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 05/10/2017] [Indexed: 12/27/2022]
Abstract
AIMS/HYPOTHESIS Recent clinical studies indicate that glucagon-like peptide-1 (GLP-1) analogues prevent acute cardiovascular events in type 2 diabetes mellitus but their mechanisms remain unknown. In the present study, the impact of GLP-1 analogues and their potential underlying molecular mechanisms in insulin resistance and atherosclerosis are investigated. METHODS Atherosclerosis development was evaluated in Apoe -/- Irs2 +/- mice, a mouse model of insulin resistance, the metabolic syndrome and atherosclerosis, treated with the GLP-1 analogues lixisenatide or liraglutide. In addition, studies in Apoe -/- Irs2 +/- mice and mouse-derived macrophages treated with lixisenatide were performed to investigate the potential inflammatory intracellular pathways. RESULTS Treatment of Apoe -/- Irs2 +/- mice with either lixisenatide or liraglutide improved glucose metabolism and blood pressure but this was independent of body weight loss. Both drugs significantly decreased atheroma plaque size. Compared with vehicle-treated control mice, lixisenatide treatment generated more stable atheromas, with fewer inflammatory infiltrates, reduced necrotic cores and thicker fibrous caps. Lixisenatide-treated mice also displayed diminished IL-6 levels, proinflammatory Ly6Chigh monocytes and activated T cells. In vitro analysis showed that, in macrophages from Apoe -/- Irs2 +/- mice, lixisenatide reduced the secretion of the proinflammatory cytokine IL-6 accompanied by enhanced activation of signal transducer and activator of transcription (STAT) 3, which is a determinant for M2 macrophage differentiation. STAT1 activation, which is essential for M1 phenotype, was also diminished. Furthermore, atheromas from lixisenatide-treated mice showed higher arginase I content and decreased expression of inducible nitric oxide synthase, indicating the prevalence of the M2 phenotype within plaques. CONCLUSIONS/INTERPRETATION Lixisenatide decreases atheroma plaque size and instability in Apoe -/- Irs2 +/- mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation. This study identifies a critical role for this drug in macrophage polarisation inside plaques and provides experimental evidence supporting a novel mechanism of action for GLP-1 analogues in the reduction of cardiovascular risk associated with insulin resistance.
Collapse
Affiliation(s)
- Ángela Vinué
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
| | - Jorge Navarro
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
- Clinic Hospital and Department of Medicine, University of Valencia, Institute of Health Research-INCLIVA, Valencia, Spain
- CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain
| | | | - Marta García-Cubas
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
| | - Irene Andrés-Blasco
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
| | - Sergio Martínez-Hervás
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
- Endocrinology and Nutrition Department, Clinic Hospital and Department of Medicine, University of Valencia, Valencia, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - José T Real
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
- Endocrinology and Nutrition Department, Clinic Hospital and Department of Medicine, University of Valencia, Valencia, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - Juan F Ascaso
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain
- Endocrinology and Nutrition Department, Clinic Hospital and Department of Medicine, University of Valencia, Valencia, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVA, Avda Menéndez Pelayo 4, 46010, Valencia, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.
| |
Collapse
|
16
|
Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. J Endocrinol 2015; 227:179-91. [PMID: 26423094 DOI: 10.1530/joe-15-0219] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/30/2015] [Indexed: 12/15/2022]
Abstract
Metabolic syndrome and type 2 diabetes mellitus constitute a major problem to global health, and their incidence is increasing at an alarming rate. Non-alcoholic fatty liver disease, which affects up to 90% of obese people and nearly 70% of the overweight, is commonly associated with MetS characteristics such as obesity, insulin resistance, hypertension and dyslipidemia. In the present study, we demonstrate that hepatic lipase (HL)-inactivation in mice fed with a high-fat, high-cholesterol diet produced dyslipidemia including hypercholesterolemia, hypertriglyceridemia and increased non-esterified fatty acid levels. These changes were accompanied by glucose intolerance, pancreatic and hepatic inflammation and steatosis. In addition, compared with WT mice, HL(-/-) mice exhibited enhanced circulating MCP1 levels, monocytosis and higher percentage of CD4+Th17+ cells. Consistent with increased inflammation, livers from HL(-/-) mice had augmented activation of the stress SAPK/JNK- and p38-pathways compared with the activation levels of the kinases in livers from WT mice. Analysis of HL(-/-) and WT mice fed regular chow diet showed dyslipidemia and glucose intolerance in HL(-/-) mice without any other changes in inflammation or hepatic steatosis. Altogether, these results indicate that dyslipidemia induced by HL-deficiency in combination with a high-fat, high-cholesterol diet promotes hepatic steatosis and inflammation in mice which are, at least in part, mediated by the activation of the stress SAPK/JNK- and p38-pathways. Future studies are warranted to asses the viability of therapeutic strategies based on the modulation of these kinases to reduce hepatic steatosis associated to lipase dysfunction.
Collapse
Affiliation(s)
- Irene Andrés-Blasco
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Andrea Herrero-Cervera
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Ángela Vinué
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Sergio Martínez-Hervás
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Laura Piqueras
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - María Jesús Sanz
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Deborah Jane Burks
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain Institute of Health Research-INCLIVAAvenida Menéndez Pelayo, 4, 46010 Valencia, SpainEndocrinology and Nutrition Department Clinic Hospital and Department of MedicineUniversity of Valencia, Valencia, SpainCIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM)Valencia, SpainDepartment of FarmacologyUniversity of Valencia, Valencia, SpainCentro de Investigación Príncipe FelipeValencia, Spain
| |
Collapse
|
17
|
Vinué Á, Andrés-Blasco I, Herrero-Cervera A, Piqueras L, Andrés V, Burks DJ, Sanz MJ, González-Navarro H. Ink4/Arf locus restores glucose tolerance and insulin sensitivity by reducing hepatic steatosis and inflammation in mice with impaired IRS2-dependent signalling. Biochim Biophys Acta Mol Basis Dis 2015; 1852:1729-42. [PMID: 26022372 DOI: 10.1016/j.bbadis.2015.05.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 05/15/2015] [Accepted: 05/20/2015] [Indexed: 01/12/2023]
Abstract
Single nucleotide polymorphisms near the Ink4/Arf locus have been associated with type-2 diabetes mellitus. Previous studies indicate a protective role of the locus in the carbohydrate metabolism derangement associated with ageing in wild-type mice. The present study demonstrates that the increased Ink4/Arf locus expression in 1-year-old mice, partially-deficient for the insulin receptor substrate (IRS)2 (Irs2+/-SuperInk4/Arf mice) ameliorates hepatic steatosis, inflammation and insulin resistance. Irs2+/-SuperInk4/Arf mice displayed improved glucose tolerance and insulin sensitivity compared with Irs2+/- mice which were glucose intolerant and insulin resistant compared with age-matched wild-type mice. These changes in Irs2+/- mice were accompanied by enhanced hepatic steatosis, proinflammatory macrophage phenotype, increased Ly6C(hi)-monocyte percentage, T-lymphocyte activation and MCP1 and TNF-α cytokine levels. In Irs2+/-SuperInk4/Arf mice, steatosis and inflammatory parameters were markedly reduced and similar to those of wild-type counterparts. In vivo insulin signalling also revealed reduced activation of the IRS/AKT-dependent signalling in Irs2+/- mice. This was restored upon increased locus expression in Irs2+/-SuperInk4/Arf mice which display similar activation levels as those for wild-type mice. In vivo treatment of Irs2+/-SuperInk4/Arf mice with TNF-α diminished insulin canonical IRS/AKT-signalling and enhanced the stress SAPK/JNK-phosphoSer307IRS1-pathway suggesting that cytokine levels might potentially affect glucose homeostasis through changes in these insulin-signalling pathways. Altogether, these results indicate that enhanced Ink4/Arf locus expression restores glucose homeostasis and that this is associated with diminished hepatic steatosis and inflammation in mice with insulin resistance. Therefore, pharmacological interventions targeted to modulate the Ink4/Arf locus expression could be a tentative therapeutic approach to alleviate the inflammation associated with insulin resistance.
Collapse
Affiliation(s)
- Ángela Vinué
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain
| | | | | | - Laura Piqueras
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain
| | - Vicente Andrés
- Department of Atherothrombosis, Imaging and Epidemiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Deborah J Burks
- Centro de Investigación Príncipe Felipe (CIPF), 46012 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Spain
| | - María Jesús Sanz
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain; Departamento de Farmacología, Universidad de Valencia, 46010 Valencia, Spain
| | - Herminia González-Navarro
- Institute of Health Research-INCLIVA, 46010 Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Spain.
| |
Collapse
|